<DOC>
	<DOCNO>NCT00396786</DOCNO>
	<brief_summary>The purpose study assess different dos new drug ( BAY 59-7939 ) , take tablet , safe help prevent blood clot form hip replacement operation . Patients undergo hip replacement surgery risk develop blood clot . To reduce risk treatment prevent clot form routinely give . The current treatment include injection skin treatment need frequent blood test monitor level drug body . Therefore need new drug , easier give need less monitoring .</brief_summary>
	<brief_title>Dose-ranging Study Once-daily Regimen BAY 59-7939 Prevention VTE Patients Undergoing Elective Total Hip Replacement</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Male patient age 18 year postmenopausal female patient Patients schedule elective primary total hip replacement ( cement noncemented prosthesis ) Patients write informed consent participation receive detailed write oral previous information study specific procedure Related medical history : Any VTE prior randomization Myocardial infarction ( MI ) TIA ischaemic stroke within last 6 month prior randomisation History heparininduced thrombocytopenia , allergy heparin Intracerebral intraocular bleeding within last 6 month prior randomisation History gastrointestinal disease gastrointestinal bleeding within last 6 month prior study History presence gastrointestinal disease could result impaired absorption study drug ( e.g . severe active inflammatory bowel disease , short gut syndrome ) Amputation one legRelated current symptom finding : Heart insufficiency NYHA class IIIIV Congenital acquire haemorrhagic diathesis ( PT INR/aPTT within normal limit ) include patient acquire congenital thrombopathy Thrombocytopenia ( platelet &lt; 100.000/Âµl ) Macroscopic haematuria Allergy contrast medium Severe hypertension ( SBP &gt; 200 mmHg , DBP &gt; 100 mmHg ) Impaired liver function ( transaminases &gt; 2 x ULN ) Impaired renal function ( serum creatinine &gt; 1.5 x ULN creatinine clearance &lt; 30 ml/min ) Active malignant disease Presence active peptic ulcer gastrointestinal disease increase risk gastrointestinal bleeding Body weight &lt; 45 kg Drug alcohol abuse Related current treatment Patients stop therapy ( opinion investigator/physician ) anticoagulant ( e.g . phenprocoumon , warfarinsodium , heparins factor Xa inhibitor study medication ) exclude study Fibrinolytic therapy Therapy acetylic salicylic acid platelet aggregation inhibitor ( e.g . clopidogrel , dipyridamole ticlopidine ) stop one week enrolment . Patients able stop ASA therapy exclude All drug influence coagulation , ( exception : NSAIDs half life &lt; 17 hr ) allow study treatment period Systemic topical treatment azole compound ( e.g . ketoconazole , fluconazole , itraconazole ) strong CYP3A4inhibitors eg HIVprotease inhibitor . Azole compound strong CYP3A4inhibitors eg HIVprotease stop least four day enrolment Therapy another investigational product within 30 day prior start study Miscellaneous Planned intermittent pneumatic compression active treatment period Planned epidural anaesthesia indwell epidural catheter ( spinal epidural anaesthesia without indwell catheter allow ) If traumatic repeat epidural spinal puncture occur patient exclude study Concomitant participation another trial study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Prevention venous thromboembolism</keyword>
</DOC>